Results 11 to 20 of about 21,470 (167)

Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy. [PDF]

Adv Sci (Weinh)
A dual‐targeting engineered extracellular vesicles (M1‐CS‐EVs) platform is developed to redirect monocytes differentiation into anti‐tumor macrophages for glioma immunotherapy. This nanoplatform combines CAR‐mediated tumor recognition with localized CD47 blockade, leading to synergistic immune activation and potent suppression of tumor progression in ...
Pan Y, Liu X, Meng QF, Cao L, Li R, Xu Y, Zhang J, Zhao C, Rao L, Yu C.   +9 more
europepmc   +2 more sources

Targeting the CD47-SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next-generation therapeutic strategies. [PDF]

Smart Mol
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Zhou R, Jing L, Zhang J, Guo C, Yang Q.
europepmc   +2 more sources

Chemotherapy-Activated GSK3β-DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma. [PDF]

Adv Sci (Weinh)
Temozolomide treatment activates GSK3β, driving DNMT1 phosphorylation, destabilization, and CD47 promoter hypomethylation in glioblastoma. This epigenetic shift upregulates CD47, enabling TMZ‐treated GBM cells to evade macrophage phagocytosis, survive chemotherapy, and acquire resistance.
Li J, Ying S, Zhang Y, Wang J, Wan Q, Gong L, Xu D, Yang Z, Lu H, Yin Y, Fang X, Pu Z.   +11 more
europepmc   +2 more sources

CD47 (Cluster of differentiation 47): an anti-phagocytic receptor with a multitude of signaling functions

Animal Cells and Systems, 2020
CD47 is a tumor-associated antigen best known for its ability to bind counter-receptors on the surface of professional phagocytes as an immune-evasion strategy.
Pascal Leclair, Chinten James Lim
doaj   +1 more source

Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity

Nature Communications, 2020
Professional antigen presenting cells (APCs) are deterred from phagocytosing cancer cells that express CD47. Here, the authors show that in glioblastoma mouse models, temozolomide improves the phagocytosis effect of CD47 blockade in APCs and results in ...
Christina A. von Roemeling, Yifan Wang, Yaqing Qie, Hengfeng Yuan, Hai Zhao, Xiujie Liu, Zhaogang Yang, Mingming Yang, Weiye Deng, Katelyn A. Bruno, Charles K. Chan, Andrew S. Lee, Stephen S. Rosenfeld, Kyuson Yun, Aaron J. Johnson, Duane A. Mitchell, Wen Jiang, Betty Y. S. Kim   +17 more
doaj   +1 more source

Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition

mBio, 2020
It is well understood that the adaptive immune response to infectious agents includes a modulating suppressive component as well as an activating component. We now show that the very early innate response also has an immunosuppressive component. Infected
Michal Caspi Tal, Laughing Bear Torrez Dulgeroff, Lara Myers, Lamin B. Cham, Katrin D. Mayer-Barber, Andrea C. Bohrer, Ehydel Castro, Ying Ying Yiu, Cesar Lopez Angel, Ed Pham, Aaron B. Carmody, Ronald J. Messer, Eric Gars, Jens Kortmann, Maxim Markovic, Michaela Hasenkrug, Karin E. Peterson, Clayton W. Winkler, Tyson A. Woods, Paige Hansen, Sarah Galloway, Dhananjay Wagh, Benjamin J. Fram, Thai Nguyen, Daniel Corey, Raja Sab Kalluru, Niaz Banaei, Jayakumar Rajadas, Denise M. Monack, Aijaz Ahmed, Debashis Sahoo, Mark M. Davis, Jeffrey S. Glenn, Tom Adomati, Karl S. Lang, Irving L. Weissman, Kim J. Hasenkrug   +36 more
doaj   +1 more source

Preclinical efficacy and toxicity studies of a highly specific chimeric anti‐CD47 antibody

FEBS Open Bio, 2021
Cluster of differentiation 47 (CD47) is a widely expressed self‐protection transmembrane protein that functions as a critical negative regulator to induce macrophage‐mediated phagocytosis.
Zhiqiang Xu, Jing Gao, Jingyun Yao, Teddy Yang, Dongxu Wang, Chaohui Dai, Yu Ding   +6 more
doaj   +1 more source

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages

Frontiers in Immunology, 2022
Antibody-dependent cellular phagocytosis (ADCP) by macrophages, an important effector function of tumor targeting antibodies, is hampered by ‘Don´t Eat Me!’ signals such as CD47 expressed by cancer cells.
Tobias Zeller, Sebastian Lutz, Ira A. Münnich, Roland Windisch, Patricia Hilger, Tobias Herold, Tobias Herold, Tobias Herold, Natyra Tahiri, Jan C. Banck, Oliver Weigert, Oliver Weigert, Oliver Weigert, Andreas Moosmann, Andreas Moosmann, Andreas Moosmann, Michael von Bergwelt-Baildon, Michael von Bergwelt-Baildon, Michael von Bergwelt-Baildon, Cindy Flamann, Heiko Bruns, Christian Wichmann, Niklas Baumann, Thomas Valerius, Denis M. Schewe, Matthias Peipp, Thies Rösner, Andreas Humpe, Christian Kellner   +28 more
doaj   +1 more source

The landscape overview of CD47-based immunotherapy for hematological malignancies

Biomarker Research, 2023
Extensive clinical and experimental evidence suggests that macrophages play a crucial role in cancer immunotherapy. Cluster of differentiation (CD) 47, which is found on both healthy and malignant cells, regulates macrophage-mediated phagocytosis by ...
Hua Yang, Yang Xun, Hua You
doaj   +1 more source

Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors

JTO Clinical and Research Reports, 2023
Introduction: CD47 is a tumor antigen that inhibits phagocytosis leading to immune evasion. Anti-CD47 therapy is a promising new immunotherapy across numerous tumor types, but it has not been tested in thymic epithelial tumors (TETs): thymomas and thymic
Thomas Yang Sun, MD, MHS, Brandon Nguyen, BA, Simon B. Chen, MD, Yasodha Natkunam, MD, PhD, Sukhmani Padda, MD, Matt van de Rijn, MD, Robert West, MD, PhD, Joel W. Neal, MD, PhD, Heather Wakelee, MD, Jonathan W. Riess, MD, MS   +9 more
doaj   +1 more source